Wall Street analyst estimates for Ascendis Pharma A/S (ASND): consensus price target and buy/hold/sell recommendations.
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates.
Consensus price target
$307.85 (+19% vs price $257.93)
between $268.00 and $344.00 · 15 targets published in the last quarter
Closing price, Nov 4
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 24 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 26 |
| Avg rating (−2 sell to +2 buy) | 0.92 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-11 | $0.89 | ||
| 2026-08-13 | $3.29 | $1.71 | +92.4% |
| 2026-05-07 | $0.32 | $0.19 | +70.6% |
| 2026-02-11 | $-0.64 | $-0.06 | -966.7% |
| 2025-11-12 | $-1.17 | $-0.41 | -185.4% |
| 2025-08-07 | $-0.93 | $-1.42 | +34.5% |
| 2025-05-01 | $-1.66 | $-1.56 | -6.4% |
| 2025-02-12 | $-0.68 | $-1.20 | +43.3% |
Valuation Ratios
| P/E Ratio | 19.03 |
| Price / Book | 10.32 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.6M EUR | 1.5M EUR | 10.6M EUR | 13.4M EUR | 7.0M EUR | 7.8M EUR | 51.2M EUR | 266.7M EUR | 363.6M EUR | 691.7M EUR |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 3.5M EUR | 12.1M EUR | 44.4M EUR | 44.3M EUR | 103.2M EUR |
| Gross Profit | 4.6M EUR | 1.5M EUR | 10.6M EUR | 13.4M EUR | 7.0M EUR | 4.3M EUR | 39.0M EUR | 222.3M EUR | 319.4M EUR | 588.5M EUR |
| Research & Development | 66.0M EUR | 99.6M EUR | 140.3M EUR | 191.6M EUR | 260.9M EUR | 295.9M EUR | 379.6M EUR | 413.5M EUR | 307.0M EUR | 283.5M EUR |
| Selling, General & Admin | 11.5M EUR | 13.5M EUR | 25.1M EUR | 48.5M EUR | 76.7M EUR | 160.2M EUR | 215.8M EUR | 258.8M EUR | 284.5M EUR | 435.9M EUR |
| Operating Expenses | 77.5M EUR | 113.1M EUR | 165.3M EUR | 240.1M EUR | 337.6M EUR | 456.0M EUR | 600.9M EUR | 677.9M EUR | 598.1M EUR | 719.4M EUR |
| Operating Income | -72.9M EUR | -111.5M EUR | -154.8M EUR | -226.7M EUR | -330.6M EUR | -451.8M EUR | -561.8M EUR | -455.5M EUR | -278.8M EUR | -130.9M EUR |
| EBITDA | -68.0M EUR | -123.5M EUR | -129.5M EUR | -210.3M EUR | -407.8M EUR | -364.6M EUR | -529.2M EUR | -411.2M EUR | -290.0M EUR | -109.8M EUR |
| Interest Expense | 5,000 EUR | 97,000 EUR | 127,000 EUR | 1.2M EUR | 1.9M EUR | 3.9M EUR | 30.7M EUR | 44.1M EUR | 65.5M EUR | 77.5M EUR |
| Pre-tax Income | -68.7M EUR | -124.4M EUR | -130.5M EUR | -218.2M EUR | -419.2M EUR | -383.9M EUR | -577.8M EUR | -474.1M EUR | -373.2M EUR | -204.3M EUR |
| Income Tax | -227,000 EUR | -477,000 EUR | -394,000 EUR | -234,000 EUR | -219,000 EUR | -367,000 EUR | 5.4M EUR | 7.3M EUR | 4.8M EUR | 14.8M EUR |
| Net Income | -68.5M EUR | -123.9M EUR | -130.1M EUR | -218.0M EUR | -419.0M EUR | -383.6M EUR | -583.2M EUR | -481.4M EUR | -378.1M EUR | -219.0M EUR |
| EPS | -€2.58 | -€3.68 | -€3.17 | -€4.69 | -€8.28 | -€7.00 | -€10.40 | -€8.55 | -€6.53 | -€3.62 |
| EPS (Diluted) | -€2.58 | -€3.68 | -€3.17 | -€4.69 | -€8.28 | -€7.00 | -€10.40 | -€8.55 | -€6.53 | -€3.62 |
| Shares Outstanding (Diluted) | 26.6 M | 33.6 M | 41.1 M | 46.5 M | 50.6 M | 54.8 M | 56.1 M | 56.3 M | 57.9 M | 60.6 M |
Price
| Price | $257.93 (closing price, November 4, 2026) |
| Market Cap | $17.0B |
| Exchange | NASDAQ |
| Country | DK |
Related companies: INSM · UTHR · NBIX · BMRN · CORT · MBX · SEPN
Explore sector: Healthcare · Biotechnology
More sections of ASND: Overview · Financials · Valuation · Technical · Ownership
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks